Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: Results of a double-blind, randomized North American study

American Journal of Gastroenterology

Volumn 95, Issue 4, 2000, Pages 936-942

  Breiter, Jeffrey R ^a   Riff, Dennis ^b   Humphries, Thomas J ^c  

^a Manchester Memorial Hospital   (United States)

^b Associated Gastroenterology   (United States)

^c EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RABEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DUODENAL ULCER; DUODENOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PAIN MEASUREMENT; RANITIDINE; TREATMENT OUTCOME;

EID: 0034072848     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00725-5     Document Type: Article

References (24)

1. Sonnenberg A., Everhart J.E. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health. 86:1996;200-205.
2. Rosenstock S.J., Jørgensen T. Prevalence and incidence of peptic ulcer disease in a Danish County - A prospective cohort study. Gut. 36:1995;819-824.
3. Khuroo M.S., Mahajan R., Zargar S.A., et al. Prevalence of peptic ulcer in India An endoscopic and epidemiological study in urban Kashmir . Gut. 30:1989;930-934.
4. Malu A.O., Sobala G.M. Prevalence of gastric and duodenal ulcers at endoscopy in Nigerian and British patients. Afr J Med Med Sci. 24:1995;239-241.
5. Levin T.R., Schmittdiel J.A., Kunz K., et al. Costs of acid-related disorders to a health maintenance organization. Am J Med. 103:1997;520-528.
6. Dragstedt L.R., Oberhelman H.A. Jr, Woodward E.R. Physiology of gastric secretion and its relation to the ulcer problem. JAMA. 147:1951;1615-1620.
7. O'Connor H.J. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol. 29:(suppl 201):1994;11-15.
8. Dekkers C.P.M., Beker J.A., Thjodleifsson B., et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer A European multicentre study . Aliment Pharmacol Ther. 13:1999;179-186.
9. Prakash A., Faulds D. Rabeprazole. Drugs. 55:1998;261-267.
10. Yasuda S., Ohnishi A., Ogawa T., et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 32:1994;466-473.
11. Besancon M., Simon A., Sachs G., et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 272:1997;22438-22446.
12. Kovacs T.O.G., Sytnik B., Humphries T.J., et al. A low dose of a new proton pump inhibitor LY-307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology. 110:(suppl):1996;A161. (abstract).
13. Lew E.A., Barbutti R.C., Kovacs T.O.G., et al. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther. 12:1998;667-672.
14. Nakazawa S., Yoshino J., Yamachika H., et al. An evaluation of the clinical usefulness of E3810 for the treatment of gastric and duodenal ulcers Early phase II clinical trial . (in Japanese) Mod Physician. 14:1994;1-22.
15. Cloud M.L., Enas N., Humphries T.J., et al. Rabeprazole in the treatment of acid peptic diseases Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD) . Dig Dis Sci. 43:1998;993-1000.
16. Nakazawa S., Namiki M., Matsuo Y., et al. Late phase II clinical trial of E3810 (rabeprazole sodium) for the treatment of gastric and duodenal ulcers. Dose-finding study using a double-blind, comparative method. Mod Physician. 14:1994;38-68.
17. Motomura A., Arita M., Sakurai T., et al. An open, randomized dose-response trial of two doses of E3810 (rabeprazole sodium) in patients with duodenal or gastric ulcers, with 24-hour gastric pH monitoring in gastric ulcer patients. Mod Physician. 14:1994;23-37.
18. Stack W.A., Knifton A., Thirlwell D., et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol. 93:1998;1909-1913.
19. Hirai M., Azuma T., Ito S., et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterology. 30:1995;461-464.
20. Valenzuela J.E., Berlin R.G., Snape W.J., et al. U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. Dig Dis Sci. 36:1991;761-768.
21. Lanza F., Goff J., Scowcroft C., et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol. 89:1994;1191-1199.
22. Morgan D.G., Burget D.W., Howden C.W., et al. Rates of duodenal ulcer (DU) healing by drug classes A meta-analysis . Gastroenterology. 104:1993;A150. (abstract).
23. Freston J.W. Long-term acid control and proton pump inhibitors Interactions and safety issues in perspective . Am J Gastroenterol. 92:1997;51S-57S.
24. Walan A., Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol. 201:(suppl):1994;91-97.